Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0X3OI
|
|||
Former ID |
DNCL002699
|
|||
Drug Name |
TAK-700
|
|||
Synonyms |
Orteronel
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Phase 3 | [1] | |
Company |
Millennium Pharmaceuticals
|
|||
Structure |
Download2D MOL |
|||
Formula |
C18H17N3O2
|
|||
Canonical SMILES |
CNC(=O)C1=CC2=C(C=C1)C=C(C=C2)C3(CCN4C3=CN=C4)O
|
|||
InChI |
1S/C18H17N3O2/c1-19-17(22)14-3-2-13-9-15(5-4-12(13)8-14)18(23)6-7-21-11-20-10-16(18)21/h2-5,8-11,23H,6-7H2,1H3,(H,19,22)
|
|||
InChIKey |
OZPFIJIOIVJZMN-UHFFFAOYSA-N
|
|||
PubChem Compound ID | ||||
PubChem Substance ID | ||||
ChEBI ID |
CHEBI:94965
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Steroid 17-alpha-monooxygenase (S17AH) | Target Info | Modulator | [1] |
BioCyc | Superpathway of steroid hormone biosynthesis | |||
Glucocorticoid biosynthesis | ||||
Androgen biosynthesis | ||||
KEGG Pathway | Steroid hormone biosynthesis | |||
Metabolic pathways | ||||
Ovarian steroidogenesis | ||||
Prolactin signaling pathway | ||||
Pathwhiz Pathway | Androgen and Estrogen Metabolism | |||
Steroidogenesis | ||||
Reactome | Androgen biosynthesis | |||
Glucocorticoid biosynthesis | ||||
Endogenous sterols | ||||
WikiPathways | Metapathway biotransformation | |||
Steroid Biosynthesis | ||||
Oxidation by Cytochrome P450 | ||||
Metabolism of steroid hormones and vitamin D | ||||
Glucocorticoid & Mineralcorticoid Metabolism | ||||
Prostate Cancer | ||||
Phase 1 - Functionalization of compounds |
References | Top | |||
---|---|---|---|---|
REF 1 | Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J Steroid Biochem Mol Biol. 2012 Apr;129(3-5):115-28. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.